Modulation of bone homeostasis by dual drug-loaded premixed magnesium tri-magnesium phosphate bone cement for the treatment of osteoporotic vertebral compression fractures

IF 18 1区医学 Q1 ENGINEERING, BIOMEDICAL

Bioactive Materials Pub Date : 2025-09-07 DOI:10.1016/j.bioactmat.2025.08.022

Jiawei Liu , Jinjin Zhu , Takashi Goto , Shuhui Yang , Honglei Kang , Xiumei Wang , Honglian Dai

{"title":"Modulation of bone homeostasis by dual drug-loaded premixed magnesium tri-magnesium phosphate bone cement for the treatment of osteoporotic vertebral compression fractures","authors":"Jiawei Liu , Jinjin Zhu , Takashi Goto , Shuhui Yang , Honglei Kang , Xiumei Wang , Honglian Dai","doi":"10.1016/j.bioactmat.2025.08.022","DOIUrl":null,"url":null,"abstract":"<div><div>Osteoporotic vertebral compression fractures (OVCF) have emerged as a significant public health concern. Traditionally, poly(methyl methacrylate) (PMMA) has been utilized in clinical to treat OVCF. Nevertheless, its poor degradability, uncontrollable setting time, high curing temperatures, and the potential for cement leakage have limited their application. In addition, these bone cements required clinical handling, bringing inconvenience to surgery.This study developed a premixed magnesium phosphate bone cement loaded with strontium ranelate and bioglass microspheres grafted with alendronate sodium (pTMPC-SMA), to achieve regulation between osteogenesis and osteoclastogenesis on osteoporosis. The premixed cement offered storage stability, easy of use, anti-washout behavior, and sustained drug release properties. The in vivo osteoporotic rabbit vertebroplasty model demonstrated that pTMPC-SMA exhibited excellent cavity-filling adaptability, significantly enhanced new bone formation, and achieved superior osseointegration compared to the PMMA group. These findings demonstrate that pTMPC-SMA provides both excellent handling properties and osteogenic therapeutic advantages for treating osteoporosis-related bone defects.</div></div>","PeriodicalId":8762,"journal":{"name":"Bioactive Materials","volume":"54 ","pages":"Pages 631-647"},"PeriodicalIF":18.0000,"publicationDate":"2025-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioactive Materials","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452199X25003743","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Osteoporotic vertebral compression fractures (OVCF) have emerged as a significant public health concern. Traditionally, poly(methyl methacrylate) (PMMA) has been utilized in clinical to treat OVCF. Nevertheless, its poor degradability, uncontrollable setting time, high curing temperatures, and the potential for cement leakage have limited their application. In addition, these bone cements required clinical handling, bringing inconvenience to surgery.This study developed a premixed magnesium phosphate bone cement loaded with strontium ranelate and bioglass microspheres grafted with alendronate sodium (pTMPC-SMA), to achieve regulation between osteogenesis and osteoclastogenesis on osteoporosis. The premixed cement offered storage stability, easy of use, anti-washout behavior, and sustained drug release properties. The in vivo osteoporotic rabbit vertebroplasty model demonstrated that pTMPC-SMA exhibited excellent cavity-filling adaptability, significantly enhanced new bone formation, and achieved superior osseointegration compared to the PMMA group. These findings demonstrate that pTMPC-SMA provides both excellent handling properties and osteogenic therapeutic advantages for treating osteoporosis-related bone defects.

Abstract Image

查看原文本刊更多论文

双重载药预混磷酸镁三镁骨水泥对骨质疏松性椎体压缩性骨折骨平衡的调节作用

骨质疏松性椎体压缩性骨折（OVCF）已成为一个重要的公共卫生问题。传统上，聚甲基丙烯酸甲酯（PMMA）已用于临床治疗OVCF。然而，它的可降解性差、凝结时间不可控、养护温度高以及水泥渗漏的可能性限制了它的应用。此外，这些骨水泥需要临床处理，给手术带来不便。本研究研制了一种负载雷奈酸锶和阿仑膦酸钠生物玻璃微球（pTMPC-SMA）的磷酸镁预混合骨水泥，实现骨质疏松症成骨和破骨细胞发生之间的调节。该预混水泥具有储存稳定性、使用方便、抗冲刷性和药物缓释特性。体内骨质疏松兔椎体成形术模型表明，与PMMA组相比，pTMPC-SMA具有良好的腔隙填充适应性，显著增强了新骨形成，实现了更好的骨整合。这些研究结果表明，pTMPC-SMA在治疗骨质疏松相关骨缺损方面具有良好的处理性能和成骨治疗优势。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bioactive Materials Biochemistry, Genetics and Molecular Biology-Biotechnology

CiteScore

28.00

自引率

6.30%

发文量

436

审稿时长

20 days

期刊介绍： Bioactive Materials is a peer-reviewed research publication that focuses on advancements in bioactive materials. The journal accepts research papers, reviews, and rapid communications in the field of next-generation biomaterials that interact with cells, tissues, and organs in various living organisms. The primary goal of Bioactive Materials is to promote the science and engineering of biomaterials that exhibit adaptiveness to the biological environment. These materials are specifically designed to stimulate or direct appropriate cell and tissue responses or regulate interactions with microorganisms. The journal covers a wide range of bioactive materials, including those that are engineered or designed in terms of their physical form (e.g. particulate, fiber), topology (e.g. porosity, surface roughness), or dimensions (ranging from macro to nano-scales). Contributions are sought from the following categories of bioactive materials: Bioactive metals and alloys Bioactive inorganics: ceramics, glasses, and carbon-based materials Bioactive polymers and gels Bioactive materials derived from natural sources Bioactive composites These materials find applications in human and veterinary medicine, such as implants, tissue engineering scaffolds, cell/drug/gene carriers, as well as imaging and sensing devices.